The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
Covaxin was earlier approved for children 12-18 years of age
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers
The first wave of shipments includes several countries, such as Germany, France and Austria
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
Subscribe To Our Newsletter & Stay Updated
